Followers of RichTV Live should be familiar with Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF). It was one of Rich’s big winners last month and it’s a company with an incredible position in a lucrative market.
This week, BABY’s been on a tear, adding 20% value in just a few days. From its position at $0.51 on Monday, it’s now trading at $0.62—and its products have yet to hit shelves in the US or Canada. This means investors have a lot to look forward to.
“This is one of the companies that I’m really, really excited about,” says Rich. “I love companies that are going to save the world, that see a problem and have a solution. I think Else Nutrition has that kind of potential.”
Else Nutrition Receives Patent for US Adult Market
The reason for BABY’s recent jump is, in part, due to its big news yesterday.
Else Nutrition received a notice of allowance from the US Patent & Trademark Office to extend its existing patents to cover the adult market for malnutrition. This applies to Else’s proprietary formula for adults who have specific malnutrition-related conditions.
These conditions include lean body mass and declining basal metabolic rates.
To address those issues, the company’s patented composition provides necessary proteins, amino acids, and other required nutrients, all in a single food serving.
CEO and Co-Founder of Else Nutrition, Hamutal Yitzhak, considers this notice of allowance a “milestone” for the company:
“It paves the way for future, already planned, product expansion beyond the baby and toddler market segments. Furthermore, the growth of our intellectual property portfolio in the US is timely as we get set to launch our products there this year.”
“This is the kind of news that could make a stock like this skyrocket,” says Rich. “I think everybody needs to put BABY on alert today.”
The company already expects its infant formula to be ready for market in Q2 of this year. With the extension of its existing patent, Else can expect to fast-track the process of delivering its adult formula to consumers in need.
As Yitzhak further explains:
“Our 100% plant-based formulation has functional and meaningful applications to a wide range of potential consumer markets. While we remain laser-focused on the launch of our baby products, our IP can also help serve the rapidly growing $5 billion U.S. plant-based food market giving those in need, nutritious clean label offerings.”
What Sets Else Nutrition Apart
Only three primary ingredients make up Else’s patented formula. These ingredients are tapioca and two whole plants—almonds and buckwheat—in their natural forms.
On top of that, it’s also made using a clean, chemical-free process. This means the formula is free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens.
Last month, the company’s toddler formula ingredients received a favorable regulatory assessment from EAS Consulting Group, LLC. EAS offers global expertise in regulatory approvals with a specialty in FDA requirements.
This indicates that Else Nutrition should expect no barrier to entering the US market.
As the vast majority of infant formulas are milk-based or soy-based, Else’s 100% plant-based formula exists in its own market vertical. For health-conscious parents, it also represents the best option in the infant formula market, which is expected to be worth US103.75 billion by 2026.
What are your thoughts? If you think BABY is a good play, let us know about it! And keep watching RichTV Live for more updates from this and other exciting companies.
Featured image: DepositPhotos © AlikeYou
